The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Yes, the message from RM at the AGM was that all potential big pharma partners they've spoken to said they needed to see more positive data to prove the potential of the drug. Hopefully the P2 studies will deliver this. If not, it's curtains.
ATB & GLA.
I can't see anything too significant resulting from this meeting personally. It may be a nice opportunity for a bit of networking and PR, but I just can't see it making much difference to our immediate situation. Hopefully I'm wrong and WOS's....sorrry Hamm's numerous posts today of "top up now!!" and "any time now!!" sentiments will prove correct.
GLA & ATB
"This forum seems a vehicle mainly to whine, and troll each other, with the odd snippet of useful information posted by a few here and there"
Welcome to the world of LSE forums, looks like you'll enjoy it. And you ain't seen nothing yet...there's a poster called WiseOwlSpeak who mercifully has been on holiday recently. Wait until he returns, for the full undiluted experience on here...
Thanks Nessab.
"Investors should look forward to the above mentioned observational study and two trials. The outputs of these will form the basis for an expected Phase 3 study in severe anti-viral infections, expected to begin in H1 2024 and significantly advance SNG001's clinical development."
I presume they mean H1 2025 for P3 (which I think would be a bit optimistic, but hey, what do I know!)
ATB & GLA.
I'd love it, just love it, if there's a procession of great RNSs at the very moment our resident "any day now!!" BOOOOOOOOMing expert WOS is off for 2 weeks buying new pants and (hopefully) getting his Irritable Owl Syndrome sorted. Be happy!!!!!!!! X30000 BAGGER INCOMING....ANY DAY NOW!!!!! STRONG BUYING DETECTED!!!!!! BREAKOUT IMMANANT!!!!!!
Synairgens linked in has been updated with mention of the ERS presentation. At work so can't see if the posters/presentation has been uploaded to the website yet.
GLA
"Header say all"
Then proceeds to follow it with paragraphs of verbiage. Priceless. Even worse, it's the same recycled stuff day after day after day after day....
And Hamm, how do you know Doc has no shares? This is something you've stated a few times. Where's your proof?
Have a nice day all.
Thanks Nessab. To my knowledge this is Synairgen's first communication in the 10 weeks since the AGM, where they promised to communicate better with shareholders. Hopefully a signal that their Summer holidays are now over and there's more to come...
ATB & GLA
10 posts already today (almost 50% of the total).
Yes folks, after a small pause to recharge/buy new pants etc WOS is back with avengeance!! Let's hope his positivity is not mis-placed and we are not kept waiting too long for an official update...it is now September after all...
GLA.
Cont:
$10 million to Johnson & Johnson Innovation (JLABS) for a competition through Blue Knight, a BARDA-JLABS partnership.
The awards to BARDA’s Clinical Studies Network will speed the development of new vaccine candidates, providing a network of at-the-ready trials with the flexibility to pivot to the most promising new vaccines as they mature. The public can expect to see clinical trials for new vaccine candidates targeting longer-lasting protection against future variants as early as this winter under Project NextGen.
HHS’ partnership with Regeneron is advancing its efforts to prevent COVID-19 infections by developing a novel monoclonal antibody that will protect people who do not respond to or cannot take existing vaccines – a critical need and current gap in COVID-19 therapeutics. HHS and Regeneron expect that the new monoclonal antibody will enter clinical trials this fall.
The remaining awards will fund technologies that enable more efficient development and manufacturing strategies – accelerating development timelines across the board and bolstering future vaccine and therapeutic availability.
In parallel with the awards announced today, HHS continues to engage with potential partners and expects to announce additional awards before the end of this fiscal year.
If you would like to learn more about Project NextGen, please visit medicalcountermeasures.gov/nextgen/.